Our study demonstrated that combined targeting of NF-κB and EZH2 with CAPE and EPZ-6438 respectively have synergistic suppression of cancer in vitro and in vivo and therefore provides information for devising strategies of Synergistic effect for the treatment of glioblastoma. Here, EZH2 is linked to glioblastoma.